Information Provided By: 
Fly News Breaks for November 1, 2018
CI, ESRX
Nov 1, 2018 | 07:41 EDT
Leerink analyst David Larsen raised his price target for Express Scripts (ESRX) to $100 from $95 after the company reported "good" Q3 results. Following shareholder and DOJ approval on 9/17 for the pending merger with Cigna (CI), the analyst remains confident the deal will close, especially given this quarter's results. The companies continue to believe the deal will be completed by December 31, 2018, he notes. Larsen reiterates a Market Perform rating on Express Scripts' shares.
News For ESRX;CI From the Last 2 Days
There are no results for your query ESRX;CI
